Precipio, Inc. (PRPO): Price and Financial Metrics

Precipio, Inc. (PRPO): $0.59

0.01 (+0.86%)

POWR Rating

Component Grades








Add PRPO to Watchlist
Sign Up

Industry: Biotech




#339 of 455

in industry

PRPO Price/Volume Stats

Current price $0.59 52-week high $1.70
Prev. close $0.58 52-week low $0.47
Day low $0.57 Volume 20,800
Day high $0.59 Avg. volume 74,317
50-day MA $0.63 Dividend yield N/A
200-day MA $0.78 Market Cap 13.71M

PRPO Stock Price Chart Interactive Chart >

PRPO Stock Summary

  • PRPO has a higher market value than only 6.54% of US stocks; more precisely, its current market capitalization is $15,187,369.
  • Of note is the ratio of PRECIPIO INC's sales and general administrative expense to its total operating expenses; 87.44% of US stocks have a lower such ratio.
  • For PRPO, its debt to operating expenses ratio is greater than that reported by merely 14.19% of US equities we're observing.
  • If you're looking for stocks that are quantitatively similar to PRECIPIO INC, a group of peers worth examining would be ESP, BEEM, ASLE, SGA, and USLM.
  • Visit PRPO's SEC page to see the company's official filings. To visit the company's web site, go to

PRPO Valuation Summary

  • In comparison to the median Healthcare stock, PRPO's price/sales ratio is 70.59% lower, now standing at 1.5.
  • PRPO's price/sales ratio has moved up 0.3 over the prior 243 months.

Below are key valuation metrics over time for PRPO.

Stock Date P/S P/B P/E EV/EBIT
PRPO 2023-05-23 1.5 1.1 -1.4 -1.3
PRPO 2023-05-22 1.5 1.1 -1.4 -1.3
PRPO 2023-05-19 1.5 1.1 -1.4 -1.3
PRPO 2023-05-18 1.5 1.1 -1.4 -1.3
PRPO 2023-05-17 1.5 1.0 -1.3 -1.3
PRPO 2023-05-16 1.4 1.0 -1.3 -1.2

PRPO Growth Metrics

    The 2 year net cashflow from operations growth rate now stands at 13.89%.
  • Its 3 year revenue growth rate is now at 230.61%.
  • Its 5 year net cashflow from operations growth rate is now at -428.1%.
Over the past 67 months, PRPO's revenue has gone up $7,477,000.

The table below shows PRPO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 9.456 -7.621 -12.118
2022-06-30 9.487 -7.509 -10.799
2022-03-31 9.472 -7.622 -11.668
2021-12-31 8.849 -6.577 -8.53
2021-09-30 8.355 -6.628 -8.194
2021-06-30 7.736 -6.92 -9.636

PRPO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PRPO has a Quality Grade of D, ranking ahead of 7.61% of graded US stocks.
  • PRPO's asset turnover comes in at 0.324 -- ranking 58th of 76 Measuring and Control Equipment stocks.
  • ROP, AXDX, and TMO are the stocks whose asset turnover ratios are most correlated with PRPO.

The table below shows PRPO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.324 0.268 19.897
2021-03-31 0.331 0.223 15.583
2020-12-31 0.307 0.189 14.223
2020-09-30 0.247 0.135 15.678
2020-06-30 0.200 0.076 11.555
2020-03-31 0.174 0.084 12.523

PRPO Price Target

For more insight on analysts targets of PRPO, see our PRPO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $7.00 Average Broker Recommendation 1.5 (Moderate Buy)

Precipio, Inc. (PRPO) Company Bio

Precipio, Inc. operates as a biotechnology company. The Company offers medicines for oncology, cardiology, neurology, and inherited diseases. Precipio also provides specialized clinical and research services to biopharmaceutical companies developing targeted therapies. Precipio serves customers in the United States.

PRPO Latest News Stream

Event/Time News Detail
Loading, please wait...

PRPO Latest Social Stream

Loading social stream, please wait...

View Full PRPO Social Stream

Latest PRPO News From Around the Web

Below are the latest news stories about PRECIPIO INC that investors may wish to consider to help them evaluate PRPO as an investment opportunity.

Precipio’s Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® Technology

Panel-Based Approach of Driver Mutation Detection Proves Crucial for Patient CareNEW HAVEN, Conn., May 22, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. leveraged its proprietary HemeScreen technology as part of the diagnostic process to monitor a patient with a history of Chronic Myeloid Leukemia (CML) and p210 isoform expression which allowed the lab to uncover an additional oncogene isoform expression (p190). While many labs only monitor previously detected muta

Yahoo | May 22, 2023

Precipio Shares Growth Catalysts For HemeScreen

Q1 Results and catalysts show promising growth trajectoryNEW HAVEN, Conn., May 17, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be discussing on today’s shareholders call several growth catalysts that management has been tracking. The Company believes that these catalysts could serve as positive indicators of future growth for HemeScreen revenues. Distributor rep engagement increased from 16% to 37%One of the many benefits of partnering with w

Yahoo | May 17, 2023

Precipio Announces Q1-2023 Shareholder Update Call

Conference Call to be held on May 17, 2023 at 5:00 PM ETNEW HAVEN, Conn., May 15, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q1-2023 corporate update call on May 17th at 5:00 PM ET. The call will include updates on all of the company’s current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc. conference call. Pa

Yahoo | May 15, 2023

Precipio Adds Substantial Pathology Customer to its Diagnostic Services Division

Customer’s pathology services annual revenues expected to exceed $1.5MNEW HAVEN, Conn., May 04, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces another agreement with a new pathology services customer to utilize Precipio’s diagnostic services. Based on the customer’s size and expected volume, with the addition of this and other customers, Precipio anticipates that with the addition of this customer, the Company expects to reach approximately

Yahoo | May 4, 2023

Precipio Signs Another HemeScreen™ Customer

Customer’s revenues expected at $750K at full capacityNEW HAVEN, Conn., May 04, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces another agreement with a new customer to bring HemeScreen™ technology into their laboratory. With each additional customer, Precipio continues to execute on its strategy, converting pipeline prospects to actual customers, and progressing towards breakeven. The company incurs virtually no additional costs for the onbo

Yahoo | May 4, 2023

Read More 'PRPO' Stories Here

PRPO Price Returns

1-mo -3.44%
3-mo -15.45%
6-mo -24.06%
1-year -51.24%
3-year -43.27%
5-year -91.63%
YTD 7.00%
2022 -65.10%
2021 -23.67%
2020 0.98%
2019 -8.89%
2018 -87.50%

Continue Researching PRPO

Want to see what other sources are saying about Precipio Inc's financials and stock price? Try the links below:

Precipio Inc (PRPO) Stock Price | Nasdaq
Precipio Inc (PRPO) Stock Quote, History and News - Yahoo Finance
Precipio Inc (PRPO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!